As bispecifics and other complex biologics move through clinical development and into commercial programmes, downstream teams are under increasing pressure to deliver purification processes that are selective, scalable and efficient. These challenging molecules often bring impurity profiles that are difficult to resolve using standard monoclonal antibody platform approaches, from product-related variants and aggregates to host cell proteins and other closely related impurities.
This webinar will explore how an outcome-led purification strategy, rather than a platform strategy, can help accelerate process development for complex biologics while balancing impurity clearance, recovery and process understanding. The session will begin with selective capture strategies that can create more options beyond standard platform approaches. It will then move to polishing, including the growing role of mixed-mode chromatography, also referred to as multimodal chromatography, for impurity profiles that may require different separation mechanisms before scale-up.
Through case studies, the presentation will highlight selective capture of Fc and non-Fc antibodies, high-molecular-weight intermediate polish and targeted HCP polish screening as examples of how different purification approaches can support a more purposeful downstream development strategy. Attendees will see how differentiated mixed-mode chromatography can help reveal purification options that may be missed by standard platform screens, particularly where closely related impurities challenge conventional approaches.
Register for this webinar to learn how bispecific purification strategies can expand separation options, improve impurity clearance and build confidence before scale-up.
Speaker
Maelia Uy-Gomez, Field Application Scientist, Astrea Bioseparations
Maelia Uy-Gomez is a Field Application Scientist at Astrea Bioseparations where she provides technical expertise in downstream purification strategies. After receiving her undergraduate degree in Bioelectronics Engineering from UC Santa Cruz, she has worked in several biotech companies supporting R&D functions, MSAT and Process Development. Maelia has led multiple monoclonal antibody purification campaigns, optimizing chromatography techniques and scaling processes from early development to pilot-scale production.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Downstream Process Development Scientists and Engineers
- CMC Scientists
- Analytical Development Scientists
- Manufacturing Scientists
- Bioprocessing professionals working with bispecific or multispecific antibodies
What You Will Learn
Attendees will:
- Discover why complex biologics often demand complementary purification strategies, including mixed-mode chromatography, beyond standard mAb platforms
- Learn how selective capture, charge-based polishing and mixed-mode polish screening can support downstream selection decisions
- Understand how mixed-mode chromatography can expand the separation space available during condition screening and optimisation
- Gain practical insights to inform process-development decisions, make efficient use of limited development material and build confidence before scale-up
Xtalks Partner
Astrea Bioseparations
Astrea Bioseparations, a Biotage company, is a leading provider of chromatography and bioseparation solutions for the life sciences industry. With more than 30 years of experience and products used in the manufacture of over 20 approved therapeutic and medical products, Astrea Bioseparations is trusted by scientists worldwide to deliver precise, reliable purification results. Astrea Bioseparations partners closely with customers to provide scalable solutions across applications including recombinant proteins, cell and gene therapies, polishing, and plasma-derived proteins, helping bring life-improving medicines to patients.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account